Immunicum AB Release: Promising Data for Cancer Vaccine INTUVAX in the Treatment of Kidney Cancer
5/20/2013 9:51:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX™ in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of 5 months.
Help employers find you! Check out all the jobs and post your resume.
comments powered by